Development of Ocular Refraction: Lessons from Animal Experiments

Introduction p. 1
Overview on the Experimental Results in Animal Models p. 2
What Is Known About the Retinal Image Processing That Leads to Refractive Errors? p. 4
How Long Must Defocus Persist to Induce Changes in Eye Growth? p. 5
What Is Known About the Tissue Responses and the Signaling Cascade from the Retina to the Sclera? p. 5
Undercorrection, Overcorrection, and Full Correction of Myopia p. 7
Reading Glasses p. 8
Contact Lenses Versus Spectacle Lenses p. 8
Illumination, Reading Distance, Computer Work Versus Reading Text in a Book p. 9
How Long Must the Near Work Be Performed to Induce Myopia? p. 10
Night Light, Blue Light p. 10
Age Window for Intervention p. 13
Pharmacological Intervention for Myopia p. 13
Emmetropization in Hyperopia with and Without Optical Correction p. 13
Summary of Effects of Different Intervention Regimens on Myopia p. 15
References p. 15

Preschool Vision Screening: Is It Worthwhile?

Introduction p. 19
Definition of Screening p. 19
Aims of Vision Screening p. 20
Preschool Vision Screening p. 20
Definition of Preschool Vision Screening p. 20
Target Conditions for Preschool Vision Screening p. 21
Natural History of Untreated Amblyopia p. 22
Whom to Screen? p. 22
Vision Screening Methodology p. 23
What Test to Use for Screening? p. 23
Visual Acuity p. 23
Stereo Tests p. 23
Orthoptic Assessment p. 24
Photorefractive Screening p. 24
Cost-Effectiveness of Different Tests p. 24
Who Should Perform the Screening? p. 24
At What Level Should Pass/Fail Criteria Be Set? p. 24
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>When to Screen?</td>
<td>25</td>
</tr>
<tr>
<td>Treatment Outcome and Age</td>
<td>25</td>
</tr>
<tr>
<td>Testability and Age</td>
<td>26</td>
</tr>
<tr>
<td>Age at Vision Screening and Risk of New Cases or Rebounding Amblyopia</td>
<td>26</td>
</tr>
<tr>
<td>Age and Psychosocial Impact of Treatment</td>
<td>26</td>
</tr>
<tr>
<td>Current Recommendations on Suitable Age for Vision Screening</td>
<td>27</td>
</tr>
<tr>
<td>The Effect of Preschool Vision Screening</td>
<td>27</td>
</tr>
<tr>
<td>The Necessity of High Participation Rates</td>
<td>27</td>
</tr>
<tr>
<td>Evaluating the Effect of Preschool Vision Screening</td>
<td>29</td>
</tr>
<tr>
<td>What is the &quot;Best Buy&quot; for Vision Screening?</td>
<td>30</td>
</tr>
<tr>
<td>Early Versus Late Vision Screening</td>
<td>30</td>
</tr>
<tr>
<td>What Test Should Be Used?</td>
<td>31</td>
</tr>
<tr>
<td>What Age Is the &quot;Best Buy&quot; for Preschool Vision Screening?</td>
<td>31</td>
</tr>
<tr>
<td>Is Preschool Vision Screening Worthwhile?</td>
<td>32</td>
</tr>
<tr>
<td>The Risk of Losing the Nonamblyopic Eye</td>
<td>32</td>
</tr>
<tr>
<td>Is It Disabling to Be Amblyopic?</td>
<td>32</td>
</tr>
<tr>
<td>Cost-Effectiveness of Screening and Treatment for Amblyopia</td>
<td>33</td>
</tr>
<tr>
<td>Future Evidence Needed</td>
<td>34</td>
</tr>
<tr>
<td>References</td>
<td>34</td>
</tr>
</tbody>
</table>

**Modern Treatment of Amblyopia**

Introduction

What Is Amblyopia

Should Amblyopia Be Treated?

What Difference Does It Make When the Patient Is a Child?

Why Treat Amblyopia?

What Are Patient Perceptions of the Disability Due to Amblyopia?

Identification of Amblyopia

Treatment of Amblyopia

Evidence for Effectiveness of Amblyopia Treatment

Correction of Refractive Error

Patching

Atropine

Why Does Amblyopia Treatment Not Always Work?

New Developments

L-DOPA

Visual Stimulation

Translation into Practice

References

Retinopathy of Prematurity: Molecular Mechanism of Disease

Introduction

Pathogenesis: Two Phases of ROP
Phase I of ROP p. 52
Phase II of ROP p. 52
Mouse Model of ROP p. 52
Vascular Endothelial Growth Factor and Oxygen in ROP p. 52
VEGF and Phase II of ROP p. 53
VEGF and Phase I of ROP p. 53
Other Growth Factors Are Involved in ROP p. 54
IGF-1 Deficiency in the Preterm Infant p. 54
GH and IGF-1 in Phase II of ROP p. 55
IGF-1 and VEGF Interaction p. 55
Low Levels of IGF-I and Phase I of ROP p. 56
Clinical Studies: Low IGF-1 Is Associated with Degree of ROP p. 56
Low IGF-1 Is Associated with Decreased Vascular Density p. 56
IGF-1 and Brain Development p. 57
Conclusion: A Rationale for the Evolution of ROP p. 57
References p. 58
Screening for Retinopathy of Prematurity
Introduction p. 63
The Disease p. 64
Classification p. 65
Treatment Requiring ROP p. 65
Treatment of Acute ROP p. 69
Epidemiology of ROP p. 69
Risk Factors p. 70
Incidence of ROP p. 70
Screening Guidelines p. 72
Screening Methods p. 73
Conventional Screening p. 73
Digital Photography p. 75
Telemedicine p. 76
Conclusions p. 77
References p. 77
Controversies in the Management of Infantile Cataract
Introduction p. 81
Epidemiology p. 81
Optimal Age for Infantile Cataract Surgery p. 82
Aphakic Glaucoma p. 83
Pupillary Membranes p. 83
Lens Reproliferation p. 84
General Anesthesia During the Neonatal Period p. 84
Visual Rehabilitation in Children with a Unilateral Congenital Cataract p. 84
Visual Rehabilitation in Children with Bilateral Congenital Cataracts p. 85
Contact Lenses p. 85
Intraocular Lenses p. 85
Surveys of North American Pediatric Ophthalmologists p. 87
Infant Aphakia Treatment Study p. 89
Eligibility Criteria p. 89
Surgical Procedure for Infants Randomized to Contact Lenses p. 89
Surgical Procedure for Infants Randomized to IOL p. 89
Type of IOL p. 90
IOL Power p. 90
Bilateral Simultaneous Surgery p. 91
Endophthalmitis p. 91
Visual Rehabilitation p. 92
References p. 92
Management of Infantile Glaucoma
Classification p. 95
Diagnostic Aspects p. 96
Clinical Background p. 96
Tonometry p. 97
Optic Disc Evaluation p. 97
Sonography p. 98
Corneal Morphology p. 98
Visual Field Testing p. 99
Objective Refraction p. 99
Medical Treatment p. 100
Miotics p. 100
Beta-Blockers p. 101
Carbonic Anhydrase Inhibitors p. 101
Prostaglandins p. 101
Alpha-2 Agonists p. 101
Surgical Therapy p. 101
Gonitomy p. 102
Trabeculotomy p. 102
Trabeculotomy Combined with Trabeculectomy p. 103
Trabeculectomy p. 103
Use of Antifibrotic Agents p. 104
Glaucoma Implants p. 104
Nonperforating Glaucoma Surgery p. 105
Cyclodialysis p. 105
Cyclodestructive Procedures p. 105
Surgical iridectomy (Laser Iridotomy) p. 106
Introduction p. 157
Clinical Findings p. 157
Differential Diagnosis p. 157
Molecular Genetics p. 158
GUCY-2D (LCA1 Locus) p. 160
RPE65 (LCA2) p. 160
CRX p. 162
AIPL1 (LCA4) p. 164
RPGRIP1 (LCA6) p. 165
TULP1 p. 166
CRB1 p. 167
RDH12 p. 169
Other Loci p. 169
Heterozygous Carriers p. 170
Future Therapeutic Avenues p. 170
Gene Therapy p. 170
Retinal Transplantation and Stem Cell Therapy p. 171
Pharmacological Therapies p. 171
References p. 172
Childhood Stationary Retinal Dysfunction Syndromes
Introduction p. 179
Stationary Retinal Dysfunction Syndromes p. 182
Rod Dysfunction Syndromes (Stationary Night Blindness) p. 182
Cone Dysfunction Syndromes p. 184
Management of Stationary Retinal Dysfunction Syndromes p. 188
Conclusions p. 188
References p. 189
Childhood Retinal Detachment
Introduction p. 191
Trauma p. 192
Blunt Ocular Trauma p. 192
Penetrating Ocular Trauma p. 193
Nontraumatic Retinal Dialysis p. 193
Familial Retinal Detachment p. 194
The Stickler Syndromes p. 194
Kniest Syndrome p. 197
Spondyloepiphyseal Dysplasia Congenita p. 197
Spondyloepimetaphyseal Dysplasia (Strudwick Type) p. 198
Vitreoretinopathy Associated with Phalangeal Epiphyseal Dysplasia p. 198
Dominant Rhegmatogenous Retinal Detachment p. 198
Marfan Syndrome p. 198
Ehlers-Danlos Syndrome p. 198
Wagner Vitreoretinopathy p. 199
X-Linked Retinoschisis p. 199
Familial Exudative Vitreoretinopathy p. 199
Norrie Disease p. 200
Incontinentia Pigmenti p. 200
Retinal Detachment Complicating Developmental Abnormalities p. 201
Congenital Cataract p. 201
Ocular Coloboma p. 201
Optic Disc Pits and Serous Macular Detachment p. 201
Retinopathy of Prematurity p. 202
Other p. 202
Inflammatory or Infectious p. 202
Exudative Retinal Detachment p. 202
Prophylaxis in Rhegmatogenous Retinal Detachment p. 203
References p. 203
Eye Manifestations of Intrauterine Infections
Introduction p. 205
Toxoplasma gondii p. 205
Agent and Epidemiology p. 205
Diagnosis p. 205
Systemic Manifestations p. 206
Eye Manifestations p. 206
Treatment p. 207
Prevention p. 207
Rubella Virus p. 207
Agent and Epidemiology p. 207
Transmission p. 207
Diagnosis p. 208
Systemic Manifestations p. 208
Eye Manifestations p. 208
Treatment p. 209
Prevention p. 209
Cytomegalovirus p. 209
Agent and Epidemiology p. 209
Transmission p. 209
Diagnosis p. 209
Systemic Manifestations p. 209
Eye Manifestations p. 209
Treatment p. 210
Prevention p. 210